Vera Therapeutics Inc’s recent filing unveils that its Officer Carter Jason S acquired Company’s shares for reported $0.11 million on Nov 21 ’25. In the deal valued at $27.87 per share,3,864 shares were bought.
Then, Young Joseph R sold 15,000 shares, generating $435,874 in total proceeds. Upon selling the shares at $29.06, the SVP, FINANCE, CHIEF ACCT OFFCR now owns 47,839 shares.
Before that, ENRIGHT PATRICK G bought 209,393 shares. Vera Therapeutics Inc shares valued at $4,369,676 were divested by the Director at a price of $20.87 per share. As a result of the transaction, ENRIGHT PATRICK G now holds 3,569,522 shares, worth roughly $104.37 million.
BofA Securities initiated its Vera Therapeutics Inc [VERA] rating to a Buy in a research note published on October 16, 2025; the price target was $48. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early August from “an Outperform” to “a Peer perform”. Wolfe Research started covering the stock on February 04, 2025. It rated VERA as “an Outperform”.
Price Performance Review of VERA
On Monday, Vera Therapeutics Inc [NASDAQ:VERA] saw its stock jump 2.74% to $29.24. Over the last five days, the stock has lost -0.75%. Vera Therapeutics Inc shares have fallen nearly -36.09% since the year began. Nevertheless, the stocks have fallen -30.86% over the past one year. While a 52-week high of $51.27 was reached on 01/06/25, a 52-week low of $18.53 was recorded on 04/09/25.
Levels Of Support And Resistance For VERA Stock
The 24-hour chart illustrates a support level at 28.47, which if violated will result in even more drops to 27.69. On the upside, there is a resistance level at 29.72. A further resistance level may holdings at 30.19.
How much short interest is there in Vera Therapeutics Inc?
A steep rise in short interest was recorded in Vera Therapeutics Inc stocks on 2025-10-31, dropping by -0.68 million shares to a total of 9.26 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 9.94 million shares. There was a decline of -7.33%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 28, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $58 price target.
